Henry E. Pelish, serving as the Chief Scientific Officer at Nuvalent, Inc. (NASDAQ:NUVL), divested 2,111 shares of the company's Class A Common Stock. The transaction, executed on July 9, 2026, involved shares sold at a price of $123.81 each, resulting in a total value of $261,362. This sale was carried out in accordance with a Rule 10b5-1 trading plan that Pelish established on December 6, 2023. Such plans are routinely implemented in advance to address tax withholding responsibilities linked to the vesting of previously granted equity awards. After this transaction, Pelish continues to hold 63,493 shares of Nuvalent Class A Common Stock directly.
The insider sale takes place as Nuvalent's stock price hovers near its 52-week high of $123.86. Over the past year, the stock has delivered a 51% return. According to InvestingPro analysis, Nuvalent appears overvalued relative to its Fair Value estimate, positioning it among companies on the most overvalued list. Investors seeking deeper insights can access additional InvestingPro Tips and comprehensive analysis for NUVL.
In other recent developments, GSK announced a $10.6 billion agreement to acquire Nuvalent. The transaction is structured as an all-cash offer of $124 per share and includes three lung cancer products, representing a 40% premium to Nuvalent's last closing price. The acquisition will bring GSK two late-stage drug candidates, zidesamtinib and neladalkib, both under FDA review with decision dates set for later in 2026.
Following the acquisition announcement, UBS downgraded Nuvalent's stock rating to Neutral from Buy, adjusting the price target to $124. Similarly, Bernstein SocGen Group downgraded Nuvalent to Market Perform from Outperform, lowering its price target to $124. Meanwhile, Bernstein had previously reiterated an Outperform rating and a $172 price target before the acquisition news. Leerink also reiterated an Outperform rating with a $165 price target after reviewing ASCO data with Nuvalent's management. These developments reflect significant analyst activity in response to the acquisition announcement.
Nuvalent
Follow
Analyze NUVL
Included in our AI-picked strategies
·Review strategies123.90▲+0.07(+0.06%)Closed·15:59:59·USD123.900.00(0.00%)After Hours·16:28:461D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00123.825123.85123.875123.9Analyze NUVLThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is NUVL undervalued—or a trap?Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what NUVL is really worth.Get instant clarity on NUVL—plus thousands of other stocks—before the opportunity disappears.July Sale - 60% Off InvestingPro